BRAF inhibitor-induced panniculitis in patients treated for stage IV metastatic melanoma: a case series

David J. Bartlett; Andrew J. Erie; Francis I. Baffour; Stephen M. Broski; Katrina N. Glazebrook

doi:10.1007/s00256-020-03665-9

BRAF inhibitor-induced panniculitis in patients treated for stage IV metastatic melanoma: a case series

David J. Bartlett, Andrew J. Erie, Francis I. Baffour, Stephen M. Broski, Katrina N. Glazebrook

Radiology

Research output: Contribution to journal › Article › peer-review

Abstract

BRAF and MEK inhibitor combination therapy is the standard treatment for patients with BRAF V600E mutant metastatic melanoma. Neutrophilic panniculitis is a known rare complication of BRAF inhibitor therapy and can act as a potential mimic of melanoma metastases on ¹⁸F-FDG PET/CT. In this case series, we present three cases of BRAF inhibitor-induced panniculitis in patients being treated for BRAF-mutant metastatic melanoma and emphasize the use of ultrasound to differentiate between panniculitis lesions, which are typically ill-defined echogenic masses and subcutaneous soft tissue melanoma metastases, which present as hypoechoic vascular masses.

Original language	English (US)
Pages (from-to)	1257-1262
Number of pages	6
Journal	Skeletal Radiology
Volume	50
Issue number	6
DOIs	https://doi.org/10.1007/s00256-020-03665-9
State	Published - Jun 2021

Keywords

BRAF
Diagnostic ultrasound
Melanoma
PET/CT
Panniculitis

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1007/s00256-020-03665-9

Cite this

@article{8443b0ce5d8141f6b67f311446ac903c,

title = "BRAF inhibitor-induced panniculitis in patients treated for stage IV metastatic melanoma: a case series",

abstract = "BRAF and MEK inhibitor combination therapy is the standard treatment for patients with BRAF V600E mutant metastatic melanoma. Neutrophilic panniculitis is a known rare complication of BRAF inhibitor therapy and can act as a potential mimic of melanoma metastases on 18F-FDG PET/CT. In this case series, we present three cases of BRAF inhibitor-induced panniculitis in patients being treated for BRAF-mutant metastatic melanoma and emphasize the use of ultrasound to differentiate between panniculitis lesions, which are typically ill-defined echogenic masses and subcutaneous soft tissue melanoma metastases, which present as hypoechoic vascular masses.",

keywords = "BRAF, Diagnostic ultrasound, Melanoma, PET/CT, Panniculitis",

author = "Bartlett, {David J.} and Erie, {Andrew J.} and Baffour, {Francis I.} and Broski, {Stephen M.} and Glazebrook, {Katrina N.}",

note = "Publisher Copyright: {\textcopyright} 2020, ISS.",

year = "2021",

month = jun,

doi = "10.1007/s00256-020-03665-9",

language = "English (US)",

volume = "50",

pages = "1257--1262",

journal = "Skeletal Radiology",

issn = "0364-2348",

publisher = "Springer Verlag",

number = "6",

}

TY - JOUR

T1 - BRAF inhibitor-induced panniculitis in patients treated for stage IV metastatic melanoma

T2 - a case series

AU - Bartlett, David J.

AU - Erie, Andrew J.

AU - Baffour, Francis I.

AU - Broski, Stephen M.

AU - Glazebrook, Katrina N.

PY - 2021/6

Y1 - 2021/6

N2 - BRAF and MEK inhibitor combination therapy is the standard treatment for patients with BRAF V600E mutant metastatic melanoma. Neutrophilic panniculitis is a known rare complication of BRAF inhibitor therapy and can act as a potential mimic of melanoma metastases on 18F-FDG PET/CT. In this case series, we present three cases of BRAF inhibitor-induced panniculitis in patients being treated for BRAF-mutant metastatic melanoma and emphasize the use of ultrasound to differentiate between panniculitis lesions, which are typically ill-defined echogenic masses and subcutaneous soft tissue melanoma metastases, which present as hypoechoic vascular masses.

AB - BRAF and MEK inhibitor combination therapy is the standard treatment for patients with BRAF V600E mutant metastatic melanoma. Neutrophilic panniculitis is a known rare complication of BRAF inhibitor therapy and can act as a potential mimic of melanoma metastases on 18F-FDG PET/CT. In this case series, we present three cases of BRAF inhibitor-induced panniculitis in patients being treated for BRAF-mutant metastatic melanoma and emphasize the use of ultrasound to differentiate between panniculitis lesions, which are typically ill-defined echogenic masses and subcutaneous soft tissue melanoma metastases, which present as hypoechoic vascular masses.

KW - BRAF

KW - Diagnostic ultrasound

KW - Melanoma

KW - PET/CT

KW - Panniculitis

UR - http://www.scopus.com/inward/record.url?scp=85095613848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85095613848&partnerID=8YFLogxK

U2 - 10.1007/s00256-020-03665-9

DO - 10.1007/s00256-020-03665-9

M3 - Article

C2 - 33165713

AN - SCOPUS:85095613848

SN - 0364-2348

VL - 50

SP - 1257

EP - 1262

JO - Skeletal Radiology

JF - Skeletal Radiology

IS - 6

ER -

BRAF inhibitor-induced panniculitis in patients treated for stage IV metastatic melanoma: a case series

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this